Massachusetts Financial Services Co. MA Cuts Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Massachusetts Financial Services Co. MA lessened its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 7.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 419,490 shares of the company's stock after selling 33,887 shares during the quarter. Massachusetts Financial Services Co. MA owned 0.65% of Kymera Therapeutics worth $16,876,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Wellington Management Group LLP grew its holdings in shares of Kymera Therapeutics by 14.9% in the 4th quarter. Wellington Management Group LLP now owns 5,307,326 shares of the company's stock worth $213,514,000 after purchasing an additional 688,967 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Kymera Therapeutics by 2.8% during the fourth quarter. Vanguard Group Inc. now owns 4,887,312 shares of the company's stock worth $196,617,000 after buying an additional 133,546 shares in the last quarter. JPMorgan Chase & Co. grew its position in Kymera Therapeutics by 212.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 140,491 shares of the company's stock worth $6,649,000 after acquiring an additional 95,547 shares during the last quarter. Norges Bank acquired a new stake in Kymera Therapeutics during the 4th quarter valued at $3,670,000. Finally, Geode Capital Management LLC raised its position in Kymera Therapeutics by 5.0% in the 4th quarter. Geode Capital Management LLC now owns 1,105,487 shares of the company's stock valued at $44,484,000 after purchasing an additional 52,263 shares during the last quarter.

Remove Ads

Wall Street Analyst Weigh In

KYMR has been the topic of a number of research reports. Leerink Partners reiterated an "outperform" rating and set a $60.00 target price on shares of Kymera Therapeutics in a research report on Friday, December 27th. HC Wainwright raised their price target on Kymera Therapeutics from $54.00 to $60.00 and gave the company a "buy" rating in a report on Friday, February 28th. Stephens reissued an "overweight" rating and set a $60.00 price objective on shares of Kymera Therapeutics in a report on Tuesday, January 21st. Finally, Citigroup initiated coverage on shares of Kymera Therapeutics in a research note on Thursday, March 13th. They issued a "buy" rating and a $52.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, Kymera Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $56.36.

Kymera Therapeutics Trading Up 7.7 %

Shares of Kymera Therapeutics stock traded up $1.72 during trading on Friday, reaching $24.12. The stock had a trading volume of 938,673 shares, compared to its average volume of 549,285. The company has a market capitalization of $1.57 billion, a price-to-earnings ratio of -10.31 and a beta of 2.22. The stock has a fifty day moving average price of $31.62 and a two-hundred day moving average price of $39.76. Kymera Therapeutics, Inc. has a 52 week low of $19.45 and a 52 week high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.88) earnings per share for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.12). Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The firm had revenue of $7.39 million for the quarter, compared to analyst estimates of $14.81 million. On average, equities analysts forecast that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Insider Activity

In related news, insider Ellen Chiniara sold 2,241 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $68,238.45. Following the completion of the transaction, the insider now owns 80,085 shares of the company's stock, valued at $2,438,588.25. This represents a 2.72 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Bruce N. Jacobs sold 7,035 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $214,215.75. Following the sale, the chief financial officer now directly owns 201,886 shares in the company, valued at $6,147,428.70. The trade was a 3.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 10,659 shares of company stock valued at $324,567. 15.82% of the stock is owned by insiders.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.